AR043254A1 - Metodo para determinar la cantidad de sustancia bloqueante neuromuscular pre-sinaptica contenida en una muestra - Google Patents

Metodo para determinar la cantidad de sustancia bloqueante neuromuscular pre-sinaptica contenida en una muestra

Info

Publication number
AR043254A1
AR043254A1 ARP040100547A ARP040100547A AR043254A1 AR 043254 A1 AR043254 A1 AR 043254A1 AR P040100547 A ARP040100547 A AR P040100547A AR P040100547 A ARP040100547 A AR P040100547A AR 043254 A1 AR043254 A1 AR 043254A1
Authority
AR
Argentina
Prior art keywords
neuromuscular blocking
sample
blocking substance
synaptic neuromuscular
determining
Prior art date
Application number
ARP040100547A
Other languages
English (en)
Original Assignee
Ipsen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9953431&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR043254(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipsen Ltd filed Critical Ipsen Ltd
Publication of AR043254A1 publication Critical patent/AR043254A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Método para determinar la cantidad de sustancia bloqueante neuromuscular pre-sináptica (especialmente toxina botulínica) contenida en una muestra. En un aspecto, el método comprende los siguientes pasos: i) determinar el voltaje mínimo Vm necesario para inducir la contracción del tejido muscular, estando dicho tejido muscular conectado a un estimulador eléctrico a través de un nervio motor y con preferencia sumergido en un buffer fisiológico oxigenado que contiene glucosa; ii) agregar la muestra que contiene la sustancia bloqueante neuromuscular pre-sináptica; iii) estimular eléctricamente, a un voltaje al menos igual a Vm el tejido muscular a ciertos intervalos de tiempo; iv) comparar el efecto inducido por la muestra al efecto inducido por una sustancia de referencia y, de ese modo, determinar al cantidad de sustancia bloqueante neuromuscular pre-sináptica contenida en la muestra. Reivindicación 19: El método de cualquiera de las reivindicaciones de 1 a 14, en el cual la sustancia bloqueante neuromuscular pre-sináptica es un bungarotoxina. Reivindicación 21: Un método para determinar la cantidad de anticuerpos neutralizantes de una sustancia bloqueante neuromuscular pre-sináptica en una muestra, que comprende los siguientes pasos: i) determinar el voltaje mínimo de Vm necesario para inducir la contracción del tejido muscular, estando dicho tejido muscular conectado a un estimulador eléctrico a través de un nervio motor; ii) agregar una mezcla de la muestra a ensayar que contiene los anticuerpos neutralizantes de la sustancia bloqueante neuromuscular pre-sináptica y una cantidad determinada de dicha sustancia bloqueante neuromuscular pre-sináptica, habiéndose pre-incubado dicha muestra a una temperatura de 0 a 45° C por un período de aproximadamente 15 a 120 minutos; iii) estimular eléctricamente, a un voltaje al menos igual a Vm el tejido muscular a ciertos intervalos de tiempo; iv) comparar el efecto inducido por la mezcla al efecto inducido por una determinada cantidad de dicha sustancia bloqueante neuromuscular pre-sináptica y, de ese modo, determinar la cantidad de anticuerpos neutralizantes de la sustancia bloqueante neuromuscular pre-sináptica contenida en la muestra.
ARP040100547A 2003-02-21 2004-02-20 Metodo para determinar la cantidad de sustancia bloqueante neuromuscular pre-sinaptica contenida en una muestra AR043254A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0303997A GB2398636A (en) 2003-02-21 2003-02-21 Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample

Publications (1)

Publication Number Publication Date
AR043254A1 true AR043254A1 (es) 2005-07-20

Family

ID=9953431

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100547A AR043254A1 (es) 2003-02-21 2004-02-20 Metodo para determinar la cantidad de sustancia bloqueante neuromuscular pre-sinaptica contenida en una muestra

Country Status (15)

Country Link
US (1) US8877456B2 (es)
EP (1) EP1597584B1 (es)
JP (2) JP2006518211A (es)
KR (1) KR101161879B1 (es)
CN (1) CN100401069C (es)
AR (1) AR043254A1 (es)
AT (1) ATE378602T1 (es)
AU (1) AU2004213639B2 (es)
CA (1) CA2516377A1 (es)
DE (1) DE602004010073T2 (es)
GB (1) GB2398636A (es)
NZ (1) NZ541853A (es)
PL (1) PL377994A1 (es)
RU (1) RU2350961C2 (es)
WO (1) WO2004074838A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201708749T4 (tr) 2004-08-04 2018-03-21 Ipsen Biopharm Ltd Botuli̇num nörotoksi̇n a2 i̇çeren farmasöti̇k bi̇leşi̇m
EP1778279B1 (en) 2004-08-04 2014-12-03 Ipsen Biopharm Limited Pharmaceutical composition containing botulinum neurotoxin a2
GB2416849A (en) 2004-08-04 2006-02-08 Ipsen Ltd Method for determining the quantity of a pre-synaptic neuromuscular blocking substance in a sample
US7473559B2 (en) * 2006-04-05 2009-01-06 Charles Lee Method for measuring the content of a botulinum toxin in a formulation
EP2202518A1 (en) 2008-12-19 2010-06-30 Merz Pharma GmbH & Co.KGaA In vivo assay for quantifying clostridial neurotoxin activity
MX2012005496A (es) 2009-11-18 2012-06-14 Merz Pharma Gmbh & Co Kgaa Ensayo para cuantificar neorotoxina clostridial.
SI2761065T1 (en) 2011-09-29 2018-02-28 Cellsnap, Llc Ingredients and procedures for toxicity testing
MX360513B (es) 2013-06-28 2018-11-07 Merz Pharma Gmbh & Co Kgaa Medios y metodos para la determinacion de la actividad biologica de polipeptidos de neurotoxina en celulas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5251621A (en) * 1991-12-18 1993-10-12 Telectronics Pacing Systems, Inc. Arrhythmia control pacer using skeletal muscle cardiac graft stimulation
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
US5591217A (en) * 1995-01-04 1997-01-07 Plexus, Inc. Implantable stimulator with replenishable, high value capacitive power source and method therefor
SE9603841D0 (sv) 1996-10-18 1996-10-18 Pacesetter Ab A tissue stimulating apparatus
ES2385130T3 (es) * 1997-07-15 2012-07-18 The Regents Of The University Of Colorado, A Body Corporate Uso de terapia con neurotoxinas para el tratamiento de enfermedades urológicas y de enfermedades relacionadas

Also Published As

Publication number Publication date
GB2398636A (en) 2004-08-25
CN1751238A (zh) 2006-03-22
US20060263352A1 (en) 2006-11-23
CA2516377A1 (en) 2004-09-02
WO2004074838A1 (en) 2004-09-02
GB0303997D0 (en) 2003-03-26
JP2011254825A (ja) 2011-12-22
EP1597584A1 (en) 2005-11-23
ATE378602T1 (de) 2007-11-15
EP1597584B1 (en) 2007-11-14
AU2004213639B2 (en) 2010-04-29
AU2004213639A1 (en) 2004-09-02
RU2350961C2 (ru) 2009-03-27
DE602004010073D1 (de) 2007-12-27
JP2006518211A (ja) 2006-08-10
NZ541853A (en) 2007-02-23
RU2005129338A (ru) 2006-06-10
DE602004010073T2 (de) 2008-09-11
CN100401069C (zh) 2008-07-09
KR20050113184A (ko) 2005-12-01
KR101161879B1 (ko) 2012-07-05
PL377994A1 (pl) 2006-02-20
US8877456B2 (en) 2014-11-04

Similar Documents

Publication Publication Date Title
Graven-Nielsen et al. The peripheral apparatus of muscle pain: evidence from animal and human studies
Copp et al. The mechano‐gated channel inhibitor GsMTx4 reduces the exercise pressor reflex in decerebrate rats
Tesch et al. Skeletal muscle proteolysis in response to short-term unloading in humans
Fuchs et al. Sensitized peripheral nociception in experimental diabetes of the rat
Gustafsson et al. Effects of 3 days unloading on molecular regulators of muscle size in humans
Xian-Min et al. Response properties and descending control of rat dorsal horn neurons with deep receptive fields
Sauer et al. Rat peripheral nerve components release calcitonin gene-related peptide and prostaglandin E2 in response to noxious stimuli: evidence that nervi nervorum are nociceptors
Phillis et al. Vasoactive intestinal polypeptide excitation of central neurons
Caiozzo et al. Influence of mechanical loading on myosin heavy-chain protein and mRNA isoform expression
Cholewa et al. Basic models modeling resistance training: an update for basic scientists interested in study skeletal muscle hypertrophy
Simonetta‐Moreau et al. The pattern of excitation of human lower limb motoneurones by probable group II muscle afferents
Nó et al. Decremental conduction in peripheral nerve. Integration of stimuli in the neuron
DE3587892D1 (de) Automatische Injektionseinrichtung.
AR043254A1 (es) Metodo para determinar la cantidad de sustancia bloqueante neuromuscular pre-sinaptica contenida en una muestra
Johansson et al. Predictors for the outcome of treatment with high frequency transcutaneous electrical nerve stimulation in patients with chronic pain
Oh et al. Chemical communication between vagal afferent somata in nodose Ganglia of the rat and the Guinea pig in vitro
Aguayo et al. One bout of vibration exercise with vascular occlusion activates satellite cells
Harridge et al. Training by low‐frequency stimulation of tibialis anterior in spinal cord–injured men
Liebano et al. Effect of low‐frequency transcutaneous electrical nerve stimulation (TENS) on the viability of ischemic skin flaps in the rat: An amplitude study
BR9906926A (pt) Composições e métodos para tratamento de células tendo dna de minuto duplo
Calvino et al. Dorsal horn (convergent) neurones in the intact anaesthetized arthritic rat. II. Heterotopic inhibitory influences
Yoshikawa et al. Effects of combined treatment with blood flow restriction and low-current electrical stimulation on muscle hypertrophy in rats
Fazalbhoy et al. Tonic muscle pain does not increase fusimotor drive to human leg muscles: implications for chronic muscle pain
Mori et al. Electro-acupuncture stimulation to a hindpaw and a hind leg produces different reflex responses in sympathoadrenal medullary function in anesthetized rats
Hamamoto et al. Characterization of cutaneous primary afferent fibers excited by acetic acid in a model of nociception in frogs

Legal Events

Date Code Title Description
FG Grant, registration